List of Excipients in Branded Drug TUDORZA PRESSAIR

« Back to Dashboard

Company	Tradename	Ingredient	NDC	Excipient	Potential Generic Entry
AstraZeneca Pharmaceuticals LP	TUDORZA PRESSAIR	aclidinium bromide	0310-0800	LACTOSE MONOHYDRATE	2029-03-13
Covis Pharma US Inc	TUDORZA PRESSAIR	aclidinium bromide	70515-002	LACTOSE MONOHYDRATE	2029-03-13
Circassia Pharmaceuticals Inc	TUDORZA PRESSAIR	aclidinium bromide	72124-002	LACTOSE MONOHYDRATE	2029-03-13

TUDORZA PRESSAIR Excipient Strategy, Patent Estate, and Commercial Opportunities

Last updated: August 27, 2026

TUDORZA PRESSAIR is a dry-powder inhaler containing aclidinium bromide for twice-daily maintenance treatment of chronic obstructive pulmonary disease. Its formulation uses a simple carrier-based architecture: micronized aclidinium bromide blended with lactose monohydrate and delivered through the PRESSAIR multidose inhaler. The commercial opportunity is concentrated in generic dry-powder inhalers, lactose-carrier optimization, device substitution, combination products, and manufacturing-process know-how rather than in a broad excipient platform.

What is the TUDORZA PRESSAIR formulation?

TUDORZA PRESSAIR contains aclidinium bromide as the active pharmaceutical ingredient and lactose monohydrate as the principal excipient. Each metered dose contains 400 micrograms of aclidinium bromide and delivers approximately 375 micrograms from the mouthpiece under labeled test conditions. The product is administered by oral inhalation twice daily. [1]

Attribute	TUDORZA PRESSAIR specification
Active ingredient	Aclidinium bromide
Therapeutic class	Long-acting muscarinic antagonist
Indication	Maintenance treatment of COPD
Dosage form	Dry powder for oral inhalation
Device	PRESSAIR multidose inhaler
Nominal dose	400 mcg aclidinium bromide per actuation
Delivered dose	Approximately 375 mcg aclidinium under label test conditions
Primary excipient	Lactose monohydrate
Dose frequency	Twice daily
Approved U.S. strength	400 mcg per actuation
Key excipient issue	Potential presence of trace milk proteins in lactose

The label identifies lactose as an inactive ingredient and warns that the product may contain milk proteins. Patients with severe milk-protein allergy may face a clinically relevant risk. Lactose intolerance is a different issue and generally does not create the same inhalation-specific contraindication. [1]

How does lactose function in TUDORZA PRESSAIR?

Lactose is a carrier, dispersion aid, and powder-engineering component. It is not used only to increase bulk.

Micronized aclidinium bromide particles are difficult to meter consistently by themselves because of their small particle size, cohesive behavior, and poor flow. The lactose carrier provides a larger surface onto which the active particles can adhere during blending. During inhalation, turbulence and shear detach a portion of the active particles from the carrier and generate respirable particles capable of reaching the lower airways.

The formulation must balance several competing properties:

• Adhesion during handling, filling, and device storage.
• Detachment during inhalation.
• Fine-particle dose and aerodynamic particle-size distribution.
• Delivered-dose uniformity throughout the multidose device.
• Low moisture uptake.
• Chemical stability of aclidinium bromide.
• Reproducible performance across patient inhalation flows.

Carrier particle size, fines content, surface roughness, crystallinity, moisture content, blending energy, and active-particle size can materially change product performance. These variables are often more commercially important than the nominal excipient identity.

Why is lactose monohydrate commercially useful?

Lactose is widely available, inexpensive, pharmaceutically familiar, and compatible with established dry-powder inhaler manufacturing infrastructure. It also allows a low-dose active ingredient to be distributed through a larger powder mass with acceptable dose uniformity.

The limitations are equally important:

1. Lactose can contain trace milk proteins.
2. Moisture can alter powder cohesion and dispersion.
3. Carrier variability can affect fine-particle delivery.
4. The product depends on a patient-generated inspiratory flow rather than a propellant.
5. A lactose-based design can be difficult to differentiate commercially unless the substitute carrier produces a measurable clinical or usability benefit.

What excipient strategy protects TUDORZA PRESSAIR?

The formulation strategy is protected primarily through the combination of active-particle engineering, carrier properties, blend control, device geometry, and manufacturing specifications. A simple statement that the product contains aclidinium bromide and lactose would provide limited differentiation by itself.

The relevant protection layers are likely to include:

Protection layer	Commercial role	Generic design-around potential
Aclidinium particle size	Controls respirable fraction and dose delivery	Alternative milling, precipitation, or spray-drying process
Lactose carrier grade	Controls adhesion and detachment	Different lactose grade, morphology, or supplier
Active-to-carrier ratio	Controls dose uniformity	Modified blend composition
Fine lactose fraction	Modifies active detachment and dispersion	Adjusted fines content or engineered carrier
Moisture specification	Preserves powder performance	Alternative packaging and humidity controls
Blending process	Controls content uniformity and agglomeration	Different order of addition, energy, or residence time
Inhaler airflow path	Controls deaggregation	Alternative device resistance and cyclone geometry
Dose counter and feedback	Supports patient use and adherence	New device architecture
Manufacturing controls	Protects reproducibility	Process validation and analytical method development

The highest-value know-how is usually the relationship among these variables. A generic manufacturer can reproduce the ingredient list while failing to reproduce fine-particle performance, emitted dose, or device-to-device consistency.

What patents protect TUDORZA PRESSAIR?

TUDORZA PRESSAIR protection is divided between aclidinium chemistry, inhalation formulations, dry-powder processing, the PRESSAIR device, and regulatory exclusivity. The Orange Book is the controlling source for currently listed U.S. patents and regulatory exclusivity. [2]

Publicly available product documentation identifies the product as developed by Almirall and commercialized in the United States by AstraZeneca under a collaboration and commercialization arrangement. Almirall retained important rights outside the United States, while AstraZeneca obtained U.S. commercialization rights. [3]

The patent estate should be analyzed in four groups:

Active-ingredient patents

These patents may cover aclidinium bromide, salts, stereochemistry, pharmaceutical compositions, or therapeutic use. Their commercial relevance depends on expiration dates, patent-term adjustment, terminal disclaimers, and any applicable pediatric extension.

Formulation patents

These patents can cover:

• Aclidinium combined with lactose.
• Particle-size distributions.
• Carrier-to-active ratios.
• Dry-powder blends.
• Fine-particle fractions.
• Moisture limits.
• Specific delivered-dose or aerodynamic performance ranges.

Formulation claims are potentially valuable because they can create a barrier even after a compound patent expires. Their enforceability depends on claim construction, written-description support, enablement, and whether a generic product necessarily practices the claimed ranges.

Device patents

PRESSAIR-related protection may cover the inhaler’s airflow path, dose-metering mechanism, internal reservoir, actuation sequence, dose counter, lockout mechanism, and patient feedback system. A generic company can avoid some device claims by using a different inhaler, but that substitution creates development, human-factors, and regulatory burdens.

Method-of-use patents

Aclidinium method-of-use patents may cover maintenance treatment of COPD, twice-daily administration, or combinations with other bronchodilators. Their practical value depends on labeling, carve-out availability, induced infringement theories, and whether the protected use is central to the commercial label.

Exact live patent scope, expiration, and Orange Book status must be assessed against the current FDA Orange Book and individual USPTO records. [2,4]

When does TUDORZA PRESSAIR lose exclusivity?

TUDORZA’s principal commercial exclusivity is exposed to the expiry of relevant compound, formulation, device, and use patents rather than to the end of one single protection date. FDA approval alone does not prevent generic entry after applicable patents and regulatory exclusivities no longer block approval.

The U.S. approval date was July 24, 2012. [1] The product therefore passed the standard five-year new chemical entity exclusivity period in 2017. Any current entry barrier is primarily patent-based, subject to the specific Orange Book listings and litigation status.

Exclusivity element	Relevance to TUDORZA
New chemical entity exclusivity	Five years from U.S. approval; expired
Three-year clinical investigation exclusivity	Not the principal current barrier
Orphan exclusivity	TUDORZA is not generally treated as an orphan COPD product
Patent-term adjustment	Must be checked for each listed patent
Pediatric extension	Depends on an FDA-granted six-month extension
Orange Book patents	May delay an ANDA if timely listed and successfully enforced
Device protection	Can influence substitution but does not independently guarantee drug approval exclusivity

What generic entry risks exist for TUDORZA PRESSAIR?

The most likely generic strategies are a Paragraph IV challenge to listed patents, a non-infringement or invalidity position, or a device-and-formulation design-around.

Paragraph IV challenges

An ANDA applicant may certify that a listed patent is invalid, unenforceable, or not infringed. A Paragraph IV notice can trigger a 30-month FDA approval stay if the patent holder files an infringement action within the statutory period. [5]

For TUDORZA, a challenger would likely examine:

• Whether the aclidinium active ingredient is already unprotected.
• Whether lactose-carrier claims require narrow particle or performance ranges.
• Whether the proposed product uses the same or a different inhaler.
• Whether device claims are listed and Orange Book-eligible.
• Whether method-of-use patents can be addressed with a skinny label.
• Whether the reference listed drug’s product-by-process characteristics are necessary for bioequivalence.

Device substitution risk

Dry-powder inhalers are not interchangeable solely because they contain the same active ingredient. Device resistance, airflow path, dose metering, deaggregation, and patient instructions affect clinical performance.

A generic applicant can pursue:

1. A PRESSAIR-like device with a licensed or internally developed formulation.
2. A different dry-powder inhaler with comparative in vitro and pharmacokinetic data.
3. A capsule-based or blister-based inhaler.
4. A combination product using aclidinium with another bronchodilator.

The first route may reduce clinical and human-factors risk but increase patent exposure. The second route may improve freedom to operate but increase development cost and regulatory complexity.

What commercial opportunities exist in TUDORZA excipients?

Lactose-grade substitution

The most immediate opportunity is development of a differentiated lactose carrier. Potential variables include:

• Narrower particle-size distribution.
• Controlled fines content.
• Reduced surface defects.
• Lower moisture content.
• Improved batch-to-batch consistency.
• Reduced milk-protein contamination.
• Better performance at lower inspiratory flow.

A supplier that can demonstrate improved fine-particle dose, lower dose variability, or better humidity stability could sell a critical excipient grade to generic inhaler developers.

Lactose-free carriers

Potential alternatives include mannitol, trehalose, glucose-based carriers, engineered porous particles, phospholipid systems, and spray-dried composite particles. A lactose-free product could target patients or prescribers concerned about milk-protein contamination.

The commercial case requires more than lactose avoidance. The alternative must match or improve:

• Emitted dose.
• Fine-particle fraction.
• Chemical stability.
• Flowability.
• Device compatibility.
• Toxicological profile.
• Regulatory acceptability.
• Cost at commercial scale.

Engineered carrier systems

Engineered carriers can create stronger differentiation. Approaches include corrugated particles, porous particles, surface-modified lactose, and carrier particles with controlled roughness. These systems may reduce active-particle agglomeration and improve detachment.

The main barrier is scale-up. Laboratory improvements often disappear during commercial blending, filling, storage, or device operation.

Co-formulation opportunities

Aclidinium can be combined commercially with other long-acting bronchodilators, including beta-2 agonists. The relevant opportunity is a fixed-dose dry-powder inhaler that improves adherence by reducing dosing frequency or combining complementary mechanisms.

Combination-product development raises additional issues:

• Chemical compatibility among actives.
• Separate or common carrier populations.
• Dose proportionality.
• Cross-contamination control.
• Device dose-metering accuracy.
• Comparative clinical and pharmacokinetic requirements.
• Additional formulation and method-of-use patents.

How does TUDORZA compare with competing COPD inhalers?

TUDORZA competes with other long-acting muscarinic antagonists and fixed-dose combinations. Its principal commercial differentiation is twice-daily aclidinium delivery through a multidose dry-powder device.

Product category	Example	Delivery platform	Excipient opportunity
LAMA dry powder	TUDORZA PRESSAIR	Multidose dry-powder inhaler	Carrier engineering and device substitution
LAMA soft mist	Tiotropium products	Soft-mist inhaler	Formulation and spray-device technology
LAMA/LABA dry powder	Aclidinium/formoterol or other combinations	Dry powder	Co-formulation and blend segregation control
LAMA/LABA inhalation aerosol	Various products	Metered-dose or soft-mist systems	Suspension, propellant, or solution technology
Inhaled corticosteroid combinations	Multiple products	Dry powder or aerosol	Particle engineering and multi-component stability

TUDORZA’s lactose-based dry-powder design is easier to manufacture than some engineered aerosol systems, but it depends more heavily on carrier performance and patient inhalation technique.

What is the FDA regulatory status of TUDORZA PRESSAIR?

TUDORZA PRESSAIR was approved by FDA in 2012 for maintenance treatment of airflow obstruction in patients with COPD. It is not indicated for relief of acute bronchospasm. The product label requires two inhalations daily, approximately 12 hours apart. [1]

A generic applicant must establish pharmaceutical equivalence and bioequivalence under the applicable FDA abbreviated pathway. For orally inhaled products, FDA evaluates the formulation, device, emitted dose, aerodynamic particle-size distribution, and other product-specific performance characteristics. FDA’s product-specific guidance and general guidance for orally inhaled and nasal drug products are central to development strategy. [6,7]

A change from lactose to another carrier would not be a routine excipient substitution from a regulatory perspective. It could affect product performance sufficiently to require expanded comparative testing and a more complex development package.

Which companies are positioned to challenge TUDORZA?

The most credible challengers are established respiratory generic manufacturers and contract developers with:

• Dry-powder inhaler engineering capabilities.
• In vitro aerodynamic testing.
• Device human-factors experience.
• Controlled blending and filling infrastructure.
• FDA ANDA filing experience.
• Access to inhalation patent counsel.

Likely commercial participants include large generic companies, specialty inhalation manufacturers, and device companies partnering with API suppliers. An API-only company has limited ability to capture the full value because the commercial barrier is the integrated drug-device product.

A supplier with a proprietary lactose grade can pursue licensing or supply agreements with generic inhaler developers. A device developer can pursue a platform license covering the inhaler while allowing multiple aclidinium formulations. A formulation company can license a lactose-free carrier or engineered-particle technology.

What licensing deals affect TUDORZA?

Almirall developed aclidinium and entered into an agreement with AstraZeneca for U.S. commercialization. AstraZeneca launched TUDORZA in the United States, while Almirall retained commercialization rights in other territories under the parties’ broader arrangement. [3]

For follow-on products, the most practical licensing structures are:

Deal structure	Asset contributed	Likely economic logic
Excipient supply agreement	Qualified lactose or alternative carrier	Recurring supply revenue
Formulation license	Blend composition or particle-engineering platform	Upfront, milestones, royalties
Device license	Multidose dry-powder inhaler	Per-unit royalty or development fee
Co-development	Integrated formulation-device product	Shared development and commercialization
Regional license	Rights by geography	Lower investment with local commercialization
Patent settlement	Delayed generic launch or licensed entry	Resolves litigation risk

Any deal must allocate responsibility for device patents, formulation patents, regulatory filings, manufacturing changes, and product liability.

How strong is the TUDORZA patent estate?

The estate is strongest where formulation and device claims are tied to measurable product performance and where the generic product would need to reproduce the reference product’s inhalation characteristics. It is weaker where claims depend on broad ingredient combinations that can be avoided through a different carrier, device, or process.

Estate characteristic	Assessment
Active ingredient	Historically important; value declines after compound protection expires
Lactose excipient alone	Limited defensive value if broadly claimed
Particle engineering	Moderate to strong if claims are narrow and reproducible
Device architecture	Potentially strong but vulnerable to redesign
Manufacturing process	Strong operational barrier; enforcement can be difficult
Method of use	Depends on label language and skinny-label feasibility
Regulatory complexity	Meaningful barrier for inhaled generics
Commercial differentiation	Moderate unless linked to flow independence, safety, or adherence

The most durable commercial moat is an integrated formulation-device system supported by manufacturing controls and clinical performance, not the use of lactose alone.

What revenue exposure does TUDORZA face from generic entry?

Generic entry can reduce price and market share rapidly in COPD maintenance therapy because payers commonly encourage substitution. The effect depends on:

• Number of approved ANDAs.
• Whether a substitutable device is available.
• Formulary placement.
• Existing fixed-dose combination competition.
• Patient retention on the PRESSAIR device.
• Reimbursement treatment of branded versus generic inhalers.
• Ability to switch patients without training failures.

Revenue exposure is likely higher for the standalone LAMA product than for a differentiated combination product. A branded manufacturer can defend value through adherence programs, device familiarity, combination therapy, and supply reliability, but those measures do not eliminate price pressure after generic entry.

Key Takeaways

• TUDORZA PRESSAIR uses aclidinium bromide blended with lactose monohydrate in a multidose dry-powder inhaler.
• Lactose acts as a carrier and dispersion aid. Carrier grade and surface properties influence fine-particle delivery.
• The strongest follow-on opportunities are engineered lactose, lactose-free carriers, device substitution, and fixed-dose combinations.
• Generic risk depends on the combined drug, formulation, device, and manufacturing patent estate.
• Paragraph IV challenges are the primary U.S. pathway for attacking listed patents.
• The U.S. five-year new chemical entity exclusivity period has expired; current barriers are patent- and product-specific.
• An alternative excipient may create commercial differentiation but can increase FDA development requirements.
• The most valuable licensing assets are integrated formulation-device platforms, not commodity lactose.

FAQs

Can lactose in TUDORZA PRESSAIR cause an allergic reaction?

The principal concern is trace milk proteins that may be present in lactose, not ordinary lactose intolerance. The FDA label warns patients with severe milk-protein allergy about this risk. [1]

Is a lactose-free aclidinium inhaler commercially feasible?

Yes, but the substitute carrier must reproduce or improve dose uniformity, fine-particle delivery, stability, device compatibility, and regulatory performance. Lactose removal alone is not a sufficient product advantage.

Can a generic use the same lactose carrier as TUDORZA?

Potentially, subject to patent scope, regulatory requirements, supplier qualification, and infringement analysis. Using the same carrier may simplify development but can increase exposure to formulation and process claims.

What excipient has the greatest value in a follow-on aclidinium inhaler?

A controlled carrier grade with demonstrable improvements in low-flow dispersion, humidity stability, and batch consistency has greater value than an unmodified commodity lactose grade.

Does a different inhaler avoid all TUDORZA patent risk?

No. A different device may avoid particular device claims but can still implicate active-ingredient, formulation, process, or method-of-use patents. It also creates additional regulatory and human-factors requirements.

References

1. U.S. Food and Drug Administration. (2023). TUDORZA PRESSAIR prescribing information. AstraZeneca Pharmaceuticals LP.

2. U.S. Food and Drug Administration. (n.d.). Approved drug products with therapeutic equivalence evaluations: Orange Book. https://www.accessdata.fda.gov/scripts/cder/ob/

3. Almirall, S.A. (2012). Annual report and corporate information regarding aclidinium bromide and commercialization arrangements.

4. U.S. Patent and Trademark Office. (n.d.). Patent Center. https://patentcenter.uspto.gov/

5. U.S. Food and Drug Administration. (n.d.). Abbreviated new drug application approvals and patent certifications. https://www.fda.gov/drugs/abbreviated-new-drug-application-anda

6. U.S. Food and Drug Administration. (2023). Product-specific guidance for aclidinium bromide inhalation powder.

7. U.S. Food and Drug Administration. (2018). Metered dose inhaler and dry powder inhaler drug products: Chemistry, manufacturing, and controls documentation. Guidance for industry.